IL37 and psoriasis: Ustekinumab, the first representer of the anti-IL23 therapeutic armamentarium in psoriasis, targets the shared p40 shared subunit of both IL12 and IL23, suppressing the inflammatory cascade of TH1 and TH17 cells, respectively.